Although SYK is widely expressed in parenchymal and non-parenchymal cells of the liver, which has also been verified by us (date not show), two new inhibitors, PRT062607 and Piceatannol, have been studied in myeloid cells to reveal their protective effects on liver fibrosis and liver cancer in vivo. Here, SYK is linked to liver cancer.